Highest-materiality recent filing
Agenus Q1 net income $39.2M, revenue $33.7M; SEC closes investigation with no action
Net income of $39.2M vs loss of $26.4M in Q1 2025; total revenue $33.7M (+40% YoY).
Agenus wins dismissal of securities class action; court denies leave to amend
U.S. District Court for Massachusetts granted motion to dismiss entire securities class action against Agenus and four individual defendants.
Agenus reports $4.2M initial BOT+BAL revenue; net loss narrows to $3.1M in FY2025
Pre-commercial product revenue of $4.2M from early access programs in France and paid NPP across 30+ countries.
Zydus pays $75M cash for Agenus' biologics manufacturing facilities in Emeryville and Berkeley, CA.
Agenus appoints CEO Garo Armen as interim CFO; names Austin Charette Principal Accounting Officer
Dr. Garo Armen, age 72, Chairman and CEO, appointed interim CFO and Principal Financial Officer effective Jan 8, 2026.
Agenus lowers warrant exercise price to $7.50; Ligand releases liens on assets
Modified warrant exercise price from $17.30 to $7.50 per share as part of Amendment Agreement with Ligand.
Agenus reports Q3 net income on MiNK gain; France reimburses BOT/BAL access
France authorizes reimbursed compassionate access for BOT/BAL in refractory MSS mCRC; patients under treatment.
Agenus Q2 net loss improves; Zydus deal adds $91M; BOT/BAL Phase 3 starts Q4 2025
Q2 revenue $25.7M; YTD net loss $56.4M vs $118.3M YoY; cash burn reduced to $45.8M from $76.4M.
Agenus sells manufacturing assets to Zydus for $75M upfront; license BOT/BAL in India
Asset sale of Emeryville/ Berkeley CA facilities for $75M at closing; up to $50M additional contingent payments.
Agenus Q1 net loss $26.4M ($1.03/sh); cash burn reduced; BOT/BAL 100% pCR in dMMR CRC
Q1 2025 cash $18.5M (down from $40.4M Dec 2024); operating cash burn $25.6M vs $38.2M YoY.
Agenus Q4 net loss $46.8M; targets annual cash burn of ~$50M by mid-2025
Q4 2024 net loss $46.8M ($2.04/share); full-year net loss $232.3M ($10.59/share).
Agenus amends $10.5M notes, issues warrants at $3.25; maturity extended to July 2026
Extended maturity of $10.5M 2015 Notes from Feb 2025 to July 2026; interest rate raised from 8% to 9%.
Agenus receives termination notice from Incyte for LAG-3/TIM-3 license; rights revert to Agenus
Incyte terminates License Agreement effective Feb 4, 2026; all rights to LAG-3 and TIM-3 revert to Agenus.
Agenus strategic realignment: 60% annual cost cut, $100M cash burn target, workforce reduction
Agenus will reduce annual expenditures by 60% and target a cash burn of $100 million for fiscal year 2025.
Agenus secures $22M mortgage and announces realignment: 60% cost cut, FY25 cash burn ~$100M
$22M non-amortizing mortgage backed by Berkeley CMC facility and Vacaville land; net proceeds $20M after costs and reserve.
Agenus Q3 2024 net loss $67.2M, cash $44.8M; BOT/BAL shows MSS CRC promise
Cash $44.8M at Sept 30, 2024 (vs $76.1M Dec 2023); raised $7.1M via ATM post-quarter.
Q2 net loss $54.8M, revenue $23.5M (incl $22.6M non-cash royalty); cash $93.7M at June 30 vs $76.1M Dec 31.
BMS terminates AGEN1777 license; Agenus regains rights to TIGIT bispecific antibody
BMS voluntarily terminates AGEN1777 license agreement effective Jan 26, 2025, as part of strategic pipeline realignment.
Agenus appoints Jennifer Buell to Board of Directors, stresses BOT/BAL BLA filing
Dr. Jennifer Buell appointed to Agenus Board effective June 11, 2024.
Agenus closes $75M sale of royalty and milestone rights to Ligand
Received $75M on May 30, 2024, for sale of milestone and royalty rights to Ligand Pharmaceuticals.
Agenus signs $100M royalty financing with Ligand; $75M upfront for BOT/BAL and partner programs
Ligand pays $75M at closing for 18.75% of royalties and 31.875% of milestones on six partnered oncology programs, plus 2.625% royalty on BOT/BAL net sales.
Agenus reports Q1 net loss $63.5M; announces $100M royalty financing with Ligand
Net loss narrowed to $63.5M ($3.04/shr) from $70.9M ($4.31/shr) a year ago; revenue $28M.
Agenus reports FY2023 net loss of $257M, revenue $156M; BOT/BAL data in CRC shows 24% ORR
FY2023 revenue $156M, net loss $257M ($0.69 EPS); Q4 revenue $84M, net loss $49M ($0.13 EPS).
Agenus proposes 1-for-20 reverse stock split to regain Nasdaq $1 compliance
Reverse stock split at 1:20 ratio proposed to lift share price above $1 Nasdaq minimum.
Agenus receives $25M milestone payment from Bristol Myers Squibb for BMS-986442 trial progress
$25M payment received Jan 30, 2024, under global licensing agreement with BMS.
Agenus receives Nasdaq deficiency notice for bid price below $1.00; has 180 days to cure
On Dec 4, 2023, Nasdaq notified Agenus that its common stock's closing bid price was below $1.00 for 31 consecutive business days.
Agenus Q3 net loss $64.5M; cash falls to $106.3M; BLA for botensilimab planned mid-2024
Net loss of $64.5M for Q3 2023, compared to $56.7M in Q3 2022; nine-month loss $208.9M.
Agenus cuts workforce 25%, pauses non-core programs to focus on BOT/BAL
Workforce reduction of ~25% expected to save $2.8M by year-end; severance cost ~$1.4M.
Agenus Q2 2023 net loss $73.4M; bot/bal combo mOS 20.9 months in CRC, FDA Fast Track
Q2 revenue $25.3M, net loss $73.4M ($0.20 EPS); cash $157.6M at June 30, down from $193.4M at Dec 2022.
Agenus Q1 net loss $70.9M; botensilimab combo shows 63% 12-month OS in colorectal cancer
Revenue $22.9M, net loss $70.9M ($0.22 EPS) vs loss $50.6M ($0.19 EPS) year ago.
Agenus declares dividend of 5M shares of MiNK Therapeutics to shareholders
Record date April 17, 2023; payment no earlier than April 27 and no later than May 17, 2023.
Agenus Q4 net loss $74M; botensilimab shows 23% ORR in MSS CRC, 50% in NSCLC
Q4 2022 revenue $28.4M, net loss $74.1M ($0.24/sh); FY22 revenue $98M, net loss $230.7M ($0.78/sh).
Agenus reports Q3 net loss $56.7M, cash $218.2M; botensilimab Phase 2 trials initiated
Q3 2022 net loss $56.7M ($0.19/sh) vs prior-year net income; revenue $22.8M, down from $253M largely due to prior milestone.
Agenus Q2 net loss narrows to $49M; botensilimab shows 24% ORR in MSS CRC
Net loss of $49.2M ($0.17/share) vs $84.0M ($0.37) in Q2 2021; revenue $20.9M (up from $10.7M).
Agenus increases authorized common shares from 400M to 800M after stockholder approval
Authorized shares of common stock doubled to 800,000,000 from 400,000,000.
Agenus Q1 2022 net loss $51M; cash $263M; botensilimab to Phase 2; Gilead $5M milestone
Net loss of $51M ($0.19/share) vs $54M ($0.27/share) YoY; revenue $26M (up from $12M).
On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc. (the "Company"), informed the Company he will be resigning effective May 29, 2026.
On October 30, 2024, Ulf Wiinberg resigned as a director at Agenus Inc. (the “Company”), effective as of 5:00 p.m. Eastern Time on November 5, 2024.
On August 7, 2024, the Board of Directors (the “Board”) of Agenus elected Thomas L. Harrison to become a Class III director of Agenus with an initial term that expires at Agenus’s annual meeting of stockholders in 2027.
Dr. Jennifer Buell was appointed to the Board of Directors of Agenus Inc. (Agenus) on June 11, 2024, effective immediately.
On December 21, 2022, Wadih Jordan sent notice of his resignation as a director at Agenus Inc. (the "Company"), effective as of December 31, 2022.
Effective December 31, 2021, Dr. Jennifer Buell resigned as Agenus Inc.’s (the “Company”) President and Chief Operating Officer to become the President and Chief Executive Officer of MiNK Therapeutics, Inc. (“MiNK”), a subsidiary of the Company.
Max materiality 0.85 · Median 0.65 · Most common event other_material